A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is testing a combination of two drugs, osimertinib and tegavivint, to treat advanced lung cancer that has a specific genetic change known as an EGFR mutation. Researchers want to see if using these two medicines together is safe and effective at stopping cancer cells from growing.
This study is for adults over 18 who have been diagnosed with metastatic non-small cell lung cancer that features an EGFR mutation. Participants must be at the stage where they are ready to begin their first-line therapy for this condition.
You will receive the study medications and undergo regular health check-ups to monitor your progress and safety. This includes standard medical imaging like CT and PET scans, heart health tests, and routine blood or tissue collections to help doctors see how the treatment is working.
The study is currently taking place in Columbus, Ohio. It is currently in the active phase, but it is no longer looking for new volunteers to join.
- 1The study combines two different drugs to target cancer cell growth.
- 2Participation involves regular scans and tests to keep a close eye on your health.
- 3This trial is specifically for patients whose lung cancer has a confirmed EGFR genetic mutation.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.